시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 클라미디아 트라코마티스(CT) 및 임균(NG) 검사 시장 보고서(2025년)
Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Global Market Report 2025
상품코드 : 1824611
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,430,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,294,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,159,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계의 클라미디아 트라코마티스(CT) 및 임균(NG) 검사 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년 연평균 복합 성장률(CAGR)은 10.1%로 확대되어 32억 2,000만 달러로 성장할 것으로 예상됩니다. 예측기간의 성장은 원격의료 및 원격의료, 개인화된 의료 접근법, 포인트 오브 케어 검사의 확대, 집단 건강 관리 전략에 기인하고 있습니다. 예측기간의 주요 동향으로는 신속 POC 검사의 확대, 개별화 검사 접근법, 다중 질환 검사 플랫폼, 지역 밀착형 검사, 아웃리치 프로그램 등이 있습니다.

향후 5년간의 성장률 10.1%라는 예측은 이 시장의 지난 예측으로부터 0.9%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세의 부과는 이탈리아나 일본에서 수입되는 이중 핵산 증폭 검사(NAAT)용 카트리지나 검체 수송 시스템의 비용을 상승시켜 감염 추적을 손상시킬 가능성이나 실험실 검사 비용을 상승시킴으로써 미국의 성 감염증(STD) 관리를 혼란시킬 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 보다 광범위하게 이어질 수 있습니다.

성감염증(STI)의 만연 확대는 당면 클라미디아 트라코마티스(CT) 및 임균(NG) 검사 시장의 확대를 견인할 것으로 예측됩니다. 성 감염증은 성적 접촉을 통해 감염되는 박테리아, 바이러스, 기생충에 의한 감염이며, 불충분한 성교육, 성행위의 활성화, 사회적 낙인, 접근 장벽 등의 요인에 의해 증가 경향이 있습니다. CT 및 NG 검사는 STI 발견 및 관리에 중요한 역할을 하며 조기 진단, 치료 및 감염 예방을 촉진합니다. 예를 들어, 2023년 7월에 세계보건기구(WHO)가 보고한 것처럼, 세계에서는 매일 100만명 이상이 새롭게 STI에 감염되고 있으며, 연간 3억 7,400만명이 새롭게 감염되고 있는 것으로 추정되며, 치료 가능한 STI 4명 중 1명이 이에 해당합니다. 그 결과 성감염증의 만연이 확대되는 것이 CTNG 검사 시장의 성장 궤도를 강조하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

JHS
영문 목차

영문목차

Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) testing involves diagnosing sexually transmitted infections (STIs) caused by these bacteria in sexually active individuals, particularly those with multiple partners or engaging in unprotected sexual activity. These tests aim to identify the presence of CT and NG bacteria through various methods such as urine samples, genital area swabs, or blood tests.

The primary testing methods for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are laboratory testing and point-of-care testing. Laboratories are specialized facilities equipped with trained personnel and specialized equipment to conduct CT and NG testing on patient samples. This includes a range of products such as assays, kits, instruments, and analyzers utilizing various technologies such as isothermal nucleic acid amplification technology, polymerase chain reaction, immunodiagnostics, among others. End users of these laboratory services include diagnostic laboratories, hospitals, clinics, and other healthcare facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market research report is one of a series of new reports from The Business Research Company that provides chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market statistics, including chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing industry global market size, regional shares, competitors with a chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market share, detailed chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market segments, market trends and opportunities, and any further data you may need to thrive in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing industry. This chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market size has grown rapidly in recent years. It will grow from $1.98 billion in 2024 to $2.19 billion in 2025 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to emergence of antibiotic resistance, awareness campaigns and education, policy changes.

The chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market size is expected to see rapid growth in the next few years. It will grow to $3.22 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to telemedicine and telehealth, personalized medicine approaches, point-of-care testing expansion, population health management strategies. Major trends in the forecast period include expansion of rapid point-of-care testing, personalized testing approaches, multi-disease testing platforms, community-based testing and outreach programs.

The forecast of 10.1% growth over the next five years reflects a modest reduction of 0.9% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. sexually transmitted diseases(STD) control by increasing costs for dual Nucleic Acid Amplification Test(NAAT) testing cartridges and specimen transport systems imported from Italy and Japan, potentially compromising infection tracking and raising lab testing costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The escalating prevalence of sexually transmitted infections (STIs) is anticipated to drive the expansion of the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market in the foreseeable future. STIs, resulting from bacterial, viral, or parasitic infections transmitted through sexual contact, are on the rise due to factors such as inadequate sex education, heightened sexual activity, societal stigma, and accessibility barriers. CT and NG testing plays a crucial role in the detection and management of STIs, facilitating early diagnosis, treatment, and prevention of transmission. For instance, as reported by the World Health Organization in July 2023, over 1 million new STIs are contracted daily worldwide, with an estimated 374 million new infections occurring annually, encompassing one in four treatable STIs. Consequently, the escalating prevalence of sexually transmitted infections underscores the growth trajectory of the CTNG testing market.

Key players in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market are prioritizing the development of innovative testing solutions to address the growing need for accurate and scalable testing methods to combat STIs. One such solution is the BD COR MX/PX System, a high-throughput infectious disease molecular diagnostic platform. This sophisticated laboratory instrument is designed to rapidly analyze large numbers of samples for infectious agents. Launched by Becton Dickinson and Company in May 2022, the BD COR MX/PX System streamlines workflow in labs processing numerous infectious disease tests, including CT and NG testing. The platform automates the entire testing process using robotics and software algorithms, enhancing efficiency and potentially reducing wait times for test results. Notable features include automation, high-throughput capability, dual DNA targets, and a modular and scalable design.

In December 2023, Imaware, a US-based health testing company, acquired the consumer testing business from Binx Health for an undisclosed amount. This acquisition enables Imaware to expand its consumer diagnostics portfolio, increasing access to STI screenings and other health tests. Binx Health is a US-based company specializing in at-home and point-of-care diagnostic testing solutions, with a focus on sexual health.

Major companies operating in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthineers, Becton Dickinson and Company, Grifols SA, Hologic Inc., PerkinElmer, bioMerieux, Sysmex Corporation, Bio-Rad Laboratories, QIAGEN, Quidel Corporation, DiaSorin, Cepheid, Seegene Inc., Meridian Bioscience Inc., Sekisui Diagnostics, J. Mitra & Co. Pvt. Ltd., Atlas Medical, Hardy Diagnostics, Molbio Diagnostics Pvt. Ltd., NG Biotech

North America was the largest region in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market in 2024. The regions covered in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market includes revenues earned by entities by providing services such as diagnostic testing, sample collection, laboratory analysis, and confidential counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market also includes the sale of sample collection kits, control materials, laboratory equipment, and software solutions. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Characteristics

3. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Trends And Strategies

4. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Growth Analysis And Strategic Analysis Framework

6. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Segmentation

7. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Regional And Country Analysis

8. Asia-Pacific Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

9. China Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

10. India Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

11. Japan Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

12. Australia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

13. Indonesia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

14. South Korea Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

15. Western Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

16. UK Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

17. Germany Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

18. France Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

19. Italy Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

20. Spain Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

21. Eastern Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

22. Russia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

23. North America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

24. USA Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

25. Canada Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

26. South America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

27. Brazil Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

28. Middle East Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

29. Africa Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

30. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Competitive Landscape And Company Profiles

31. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Other Major And Innovative Companies

32. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

34. Recent Developments In The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

35. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기